These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9123004)

  • 1. Bromocriptine as an adjuvant to cyclosporine immunosuppression after renal transplantation.
    Yongjin J; ZiLin F; Zhenmei B
    Transplant Proc; 1997; 29(1-2):297. PubMed ID: 9123004
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of acute cellular rejection after azathioprine withdrawal in stable renal allograft recipients on cyclosporine, azathioprine, and prednisone.
    Fabrega AJ; Roy G; Reynolds L; Corwin C; Hunsicker L
    Transplant Proc; 1998 Jun; 30(4):1335-6. PubMed ID: 9636543
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunosuppression protocols for HLA identical renal transplant recipients.
    Keitel E; Santos AF; Alves MA; Neto JP; Schaefer PG; Bittar AE; Goldani JC; Pozza R; Bruno RM; See D; Garcia CD; Garcia VD
    Transplant Proc; 2003 May; 35(3):1074-5. PubMed ID: 12947863
    [No Abstract]   [Full Text] [Related]  

  • 4. Donor specific transfusion in kidney transplantation: effect of different immunosuppressive protocols on graft outcome.
    Barbari A; Stephan A; Masri MA; Joubran N; Dagher O; Kamel G
    Transplant Proc; 2001 Aug; 33(5):2787-8. PubMed ID: 11498161
    [No Abstract]   [Full Text] [Related]  

  • 5. Application of corbrin capsule in human renal transplantation.
    Min Z; Oi J; Zhu Y; Wei W
    Transplant Proc; 1996 Jun; 28(3):1626-8. PubMed ID: 8658813
    [No Abstract]   [Full Text] [Related]  

  • 6. Increasing incidence of steroid resistant rejection in kidney transplantation.
    Arrazola L; Sozen H; Humar A; Papalois V; Uknis M; Matas AJ
    Transplant Proc; 2000 Nov; 32(7):1767. PubMed ID: 11119926
    [No Abstract]   [Full Text] [Related]  

  • 7. Triple therapy with mycophenolate mofetil versus azathioprine.
    Muñiz ML; Amenabar J; Gómez-Ullate P; Urbizu J; Lampreabe I
    Transplant Proc; 1999; 31(1-2):1144-6. PubMed ID: 10083512
    [No Abstract]   [Full Text] [Related]  

  • 8. Bromocriptine as an adjuvant to cyclosporine immunosuppression after heart transplantation.
    Carrier M; Wild J; Pelletier LC; Copeland JG
    Ann Thorac Surg; 1990 Jan; 49(1):129-32. PubMed ID: 2297260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low incidence of rejection after synchronous pancreas-kidney transplantation with Neoral.
    Cattral MS; Hemming AW; Greig PD; Rowsell C; Chari R; Wright E; Donat D; Cole E; Levy GA
    Transplant Proc; 1998 Aug; 30(5):1946. PubMed ID: 9723346
    [No Abstract]   [Full Text] [Related]  

  • 10. Retrospective study of cyclosporine-prednisolone versus cyclosporine-azathioprine-prednisolone immunosuppression in living donor kidney transplantation.
    Reissi D; Bardideh A; Samadzadeh B; Razi A
    Transplant Proc; 1995 Oct; 27(5):2685-6. PubMed ID: 7482875
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduced severity of acute rejection in hepatitis C virus positive renal allograft recipients: are milder immunosuppressive regimens advisable?
    Pascual J; Crespo M; Mateos ML; Marcén R; Orofino L; Burgos FJ; Liaño F; Ortuño J
    Transplant Proc; 1998 Jun; 30(4):1329-30. PubMed ID: 9636540
    [No Abstract]   [Full Text] [Related]  

  • 12. Prophylactic use of deoxyspergualin improves long-term graft survival in living related renal transplant recipients transfused with donor-specific blood.
    Amada N; Okazaki H; Sato T; Miura S; Ohashi Y
    Transplant Proc; 2001 May; 33(3):2256-7. PubMed ID: 11377520
    [No Abstract]   [Full Text] [Related]  

  • 13. Neoral versus Sandimmune in kidney transplantation.
    Tisone G; Orlando G; Mercadante E; Vennarecci G; Pisani F; Buonomo O; Negrini S; Casciani CU
    Transplant Proc; 1998 Aug; 30(5):1749-50. PubMed ID: 9723265
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term results and risk factors of quadruple immunosuppression in renal transplantation.
    Hiesse C; Kriaa F; Eschwege P; Boubenider S; Marchand S; Benoit G; Charpentier B
    Transplant Proc; 1999; 31(1-2):1111-2. PubMed ID: 10083496
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Marcas LI; Manresa JM; Masramón J
    Transplant Proc; 1998 Aug; 30(5):2226-7. PubMed ID: 9723449
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized trial to evaluate the use of increasing the steroid dose during conversion from cyclosporine to azathioprine.
    Roodnat JI; Zietse R; Rischen-Vos J; van Gelder T; IJzermans JN; Weimar W
    Transplant Proc; 1998 Jun; 30(4):1199-200. PubMed ID: 9636486
    [No Abstract]   [Full Text] [Related]  

  • 17. BTI-322 for induction therapy after renal transplantation: a randomized study.
    Squifflet JP; Besse T; Malaise J; Mourad M; Delcorde C; Hope JA; Pirson Y
    Transplant Proc; 1997; 29(1-2):317-9. PubMed ID: 9123018
    [No Abstract]   [Full Text] [Related]  

  • 18. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
    Ettenger R; Cohen A; Nast C; Moulton L; Marik J; Gales B
    Transplant Proc; 1997; 29(1-2):340-1. PubMed ID: 9123030
    [No Abstract]   [Full Text] [Related]  

  • 19. Late acute rejection episodes after vascularized pancreas transplantation.
    Stratta RJ
    Transplant Proc; 1998 Jun; 30(4):1560-1. PubMed ID: 9636633
    [No Abstract]   [Full Text] [Related]  

  • 20. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
    Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.